Transaction details
On April 17, 2026, Ramiro Ribeiro, EyePoint, Inc. (NASDAQ: EYPT) Chief Medical Officer, sold 2,437 shares of the company's common stock at $15.00 per share, for total gross proceeds of $36,555. Those shares were sold the same day Ribeiro exercised 2,437 stock options with an exercise price of $8.26 per share, representing a cash outlay of $20,129 to acquire the underlying stock.
The options exercised were part of a grant that vests 25% on January 3, 2026, with the balance vesting ratably on a monthly basis over the following three years. Following the exercise and the sale, Ribeiro holds zero shares of EyePoint common stock directly and retains 80,438 stock options. The transactions were carried out pursuant to a Rule 10b5-1 trading plan.
Context on the stock and valuation
The disposition coincides with a period in which the stock has appreciated substantially - delivering a 163% return over the prior 12 months - and currently trades near a Fair Value estimated at $14.57. The sale price of $15.00 per share was modestly above that Fair Value level.
Recent financial results
EyePoint reported a sharp decline in revenue for the fourth quarter of 2025 and an earnings per share result of -$0.81, missing analysts' expectation of -$0.75. Quarterly revenue fell to $0.6 million from $11.6 million in the same quarter a year earlier. For the full year, revenue totaled $31.4 million while the company recorded a net loss of $232.0 million.
Analyst posture and clinical progress
Despite the weak near-term financials, several analysts maintained or raised their price targets and ratings. H.C. Wainwright lifted its price target to $30, citing progress in EyePoint’s diabetic macular edema trial. Chardan raised its price target to $29 and highlighted the company’s cash position of $306 million. Guggenheim reiterated a Buy rating with a $68 price target, emphasizing favorable safety data for EyePoint’s Duravyu treatment. Mizuho kept an Outperform rating with a $36 price target, noting continued progress for Duravyu.
What the transactions show
The combined option exercise and immediate sale executed under an approved trading plan left Ribeiro without direct equity while preserving a substantial option position. The broader company backdrop mixes significant recent share-price appreciation and clinical developments with material revenue contraction and an elevated full-year net loss.